ICER Releases Final Evidence Report for Hypertrophic Cardiomyopathy Drug

The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report for mavacamten, produced by MyoKardia and Bristol-Myers Squibb. The drug is used in patients diagnosed with hypertrophic cardiomyopathy (HCM). Panelists voted on the drug’s clinical effectiveness compared to disopyramide and background therapy.

ICER’s Chief Medical Officer David Rind, MD remarks, “The evidence suggests that mavacamten may deliver important health benefits for patients with a lower rate of side effects than seen with some other medications for HCM, but clinical experts differ in their opinions about the long-term clinical implications of mavacamten reducing left ventricular ejection fraction in some patients,” adding, “Additional safety data are needed to resolve these issues.” Read more here.

(Source: ICER, 11/16/21)